Glecirasib Citrate

枸橼酸戈来雷塞

Report date: 2026/02/02 10:14:18
NME

Base Information

Drug NameGlecirasib Citrate
Drug Alias Name枸橼酸格来雷塞Glecirasib枸橼酸戈来雷塞格来雷塞戈来雷塞 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKRAS G12C inhibitorsProtein allosteric inhibitors
TargetsKRAS G12C
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[8] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryMainland China
Original Approved Date2025/05/20
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJacobio Pharmaceuticals Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJacobio Pharmaceuticals Group Co LtdSun Yat-Sen UniversityJacobio Pharmaceuticals Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLung Neoplasms +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBank